Merck & Co., Inc. (NYSE:MRK) Shares Purchased by Copperwynd Financial LLC

Copperwynd Financial LLC increased its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 2.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 21,697 shares of the company’s stock after purchasing an additional 541 shares during the quarter. Merck & Co., Inc. accounts for approximately 1.0% of Copperwynd Financial LLC’s holdings, making the stock its 22nd biggest position. Copperwynd Financial LLC’s holdings in Merck & Co., Inc. were worth $1,973,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Accurate Investment Solutions Inc. increased its position in Merck & Co., Inc. by 12.0% during the 4th quarter. Accurate Investment Solutions Inc. now owns 1,065 shares of the company’s stock worth $97,000 after purchasing an additional 114 shares in the last quarter. Ellis Investment Partners LLC increased its position in Merck & Co., Inc. by 0.6% during the 4th quarter. Ellis Investment Partners LLC now owns 20,256 shares of the company’s stock worth $1,864,000 after purchasing an additional 117 shares in the last quarter. Fox Run Management L.L.C. increased its position in Merck & Co., Inc. by 4.4% during the 3rd quarter. Fox Run Management L.L.C. now owns 2,827 shares of the company’s stock worth $238,000 after purchasing an additional 118 shares in the last quarter. First Command Bank increased its position in Merck & Co., Inc. by 1.4% during the 3rd quarter. First Command Bank now owns 8,599 shares of the company’s stock worth $724,000 after purchasing an additional 118 shares in the last quarter. Finally, Allworth Financial LP increased its position in Merck & Co., Inc. by 1.9% during the 3rd quarter. Allworth Financial LP now owns 6,278 shares of the company’s stock worth $528,000 after purchasing an additional 119 shares in the last quarter. 74.51% of the stock is owned by hedge funds and other institutional investors.

MRK has been the subject of a number of recent research reports. ValuEngine cut Merck & Co., Inc. from a “hold” rating to a “sell” rating in a research report on Tuesday, January 14th. Mizuho reiterated a “buy” rating and set a $100.00 price objective on shares of Merck & Co., Inc. in a research report on Monday, January 6th. Royal Bank of Canada initiated coverage on Merck & Co., Inc. in a research report on Monday, January 6th. They set a “sector perform” rating and a $99.00 price objective for the company. UBS Group lifted their price objective on Merck & Co., Inc. from $94.00 to $99.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, Cantor Fitzgerald reiterated a “buy” rating and set a $95.00 price objective on shares of Merck & Co., Inc. in a research report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and thirteen have issued a buy rating to the company’s stock. Merck & Co., Inc. currently has a consensus rating of “Buy” and a consensus price target of $96.38.

Merck & Co., Inc. stock traded down $1.09 during midday trading on Thursday, hitting $88.56. 12,593,559 shares of the company were exchanged, compared to its average volume of 8,943,448. The company’s fifty day moving average price is $90.27 and its 200-day moving average price is $85.75. The company has a market cap of $229.06 billion, a PE ratio of 24.74, a price-to-earnings-growth ratio of 1.79 and a beta of 0.52. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.26 and a quick ratio of 0.98. Merck & Co., Inc. has a fifty-two week low of $72.05 and a fifty-two week high of $92.64.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Tuesday, October 29th. The company reported $1.51 EPS for the quarter, topping the consensus estimate of $1.24 by $0.27. The firm had revenue of $12.40 billion for the quarter, compared to analyst estimates of $11.59 billion. Merck & Co., Inc. had a return on equity of 48.16% and a net margin of 20.26%. Merck & Co., Inc.’s revenue for the quarter was up 14.9% on a year-over-year basis. During the same period in the previous year, the company posted $1.19 EPS. On average, analysts expect that Merck & Co., Inc. will post 5.16 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Wednesday, January 8th. Investors of record on Monday, December 16th were given a dividend of $0.61 per share. The ex-dividend date was Friday, December 13th. This is a positive change from Merck & Co., Inc.’s previous quarterly dividend of $0.55. This represents a $2.44 annualized dividend and a yield of 2.76%. Merck & Co., Inc.’s payout ratio is 56.22%.

In related news, EVP Julie L. Gerberding sold 102,073 shares of the business’s stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $89.34, for a total transaction of $9,119,201.82. Following the transaction, the executive vice president now directly owns 106,099 shares of the company’s stock, valued at approximately $9,478,884.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.27% of the company’s stock.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

See Also: Overbought

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.